- About Us
- Patient & Family Care
- Education & Events
- Research & Clinical Trials GeneMatch Types of Research Studies Alzheimer’s Prevention Initiative Studies Currently Enrolling Research Study Participation FAQs Brain Imaging Research Genomics Research
- For Medical Professionals
- Support Our Mission
- News & Media
Explore the new era of prevention research launched by Banner Alzheimer’s Institute.
The Alzheimer’s Prevention Initiative (API) has ignited a new era of Alzheimer’s research focusing on prevention.
Championed and led by Banner Alzheimer’s Institute, API is an international collaborative formed to launch a new era of Alzheimer’s prevention research by evaluating the most promising therapies in cognitively normal people who – based on age and genetic background – are at highest risk of developing Alzheimer’s disease symptoms as quickly as possible.
The goal of API is to identify pre-symptomatic treatments or interventions that will postpone, slow or prevent the disease’s progression.
API’s scientists, researchers and physicians collaborate with partners throughout the world and with the Arizona Alzheimer’s Consortium and the Collaboration for Alzheimer’s Prevention on:
This groundbreaking API trial includes cognitively healthy individuals who are destined to develop Alzheimer’s disease because of their genetic history. The Autosomal Dominant Alzheimer's Disease (ADAD) Trial involves approximately 300 members of an extended family in Colombia, South America. Many members of this family share a rare genetic mutation that typically triggers Alzheimer’s symptoms around age 45.
The ADAD trial focuses on whether an "anti‐amyloid” antibody treatment called crenezumab can stave off Alzheimer’s disease. Amyloid – a sticky deposit that builds up in the brains of people with Alzheimer’s disease – is thought by many researchers to play a role in the development of Alzheimer’s.
API ADAD trial partners include:
National Institutes of Health
University of Antioquia's Grupo de Neurosciencias in Medellin, Colombia
The Generation Program is made up of two clinical trials: Generation Study 1 and Generation Study 2. Each trial will last for 5 – 8 years and will be investigating treatment that may be able to prevent the onset of Alzheimer’s. These studies are not looking for people with Alzheimer’s, but rather those with a specific form of a gene that can increase the risk of developing the disease.
The goal of the Generation Program is to find out whether experimental medications can prevent the onset of Alzheimer’s symptoms. In these clinical trials, we’ll test the study medications against placebo. Research shows a link between a substance called amyloid beta and Alzheimer’s disease. The study medications may stop amyloid beta from building up in the brain. Participants in this program could advance doctors’ understanding of how to potentially prevent the onset of Alzheimer’s.
API Generation Study partners include:
National Institutes of Health
Banner Alzheimer’s Foundation
Banner Alzheimer’s Institute – in partnership with other organizations dedicated to Alzheimer’s prevention research – launched the Alzheimer’s Prevention Registry.
Through the Registry, these leading research organizations are building an online community focused on ending Alzheimer’s. The Registry connects research scientists to study participants eager to advance knowledge of Alzheimer’s and its prevention.
Why is the Registry key to Alzheimer’s prevention research? To answer this, it’s important to know that approximately 80 percent of research studies are unable to meet their initial recruiting goals. This delays the discovery of both important findings and potentially valuable treatments. By connecting scientists and the public, the Registry removes this hurdle and helps keep Alzheimer’s prevention research on track.
GeneMatch is a first-of-its-kind program designed to identify a large group of people interested in volunteering for Alzheimer’s research studies based in part on their APOE genetic information. The APOE gene is the best established genetic risk factor for late-onset Alzheimer’s disease.
GeneMatch allows for the identification of individuals who may be at varying degrees of genetic risk for developing symptoms of Alzheimer’s disease and helps match them to study opportunities in their communities in an effort to aid in the discovery of treatments that may slow or prevent the progression of Alzheimer’s disease.
GeneMatch, a program of the Alzheimer’s Prevention Registry, is enrolling people ages 55 to 75 who live in the U.S. and do not have a diagnosis of dementia or other cognitive impairment.